PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
Recruiting now · Phase 2
Conditions studied: Breast Cancer, Residual Disease, Triple Negative Breast Cancer (TNBC), Stage II/III
In brief
This is a Phase II, interventional, prospective, single-arm, multi-center study that will enroll patients with stage II/III triple negative breast cancer (TNBC) who have residual cancer burden (RCB) II/III after conventional neoadjuvant chemo-immunotherapy followed by surgery. Technological advances in ctDNA assays have improved both the sensitivity and reliability of molecular residual disease (MRD) detection to enable real-time measurement with clinical-grade assays. The primary objective of this study will be to evaluate ctDNA-based MRD status in high-risk, early-stage TNBC patients by defining the proportion of TNBC patients with MRD-only recurrence (ctDNA positive without radiographically measurable recurrence) during post-surgery surveillance. The secondary objectives will evaluate the safety, preliminary efficacy, and survival outcomes of using Dato-DXd in participants with MRD-only TNBC. Dato-DXd is an investigational antibody-drug conjugate (monoclonal antibody specific for TROP2 and a topoisomerase I (Topo-1) inhibitor) that has demonstrated promising efficacy in TNBC patients with a manageable safety profile.
Key facts
- Study ID
- NCT07069595
- Run by
- UNC Lineberger Comprehensive Cancer Center
- People needed
- 78
- Starts
- 2026-02-26
- Expected to finish
- 2032-11-01
- Last updated by the study team
- 2026-04-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Written informed consent was obtained to participate in the study, and HIPAA authorization for the release of personal health information.
- Participant is willing and able to comply with study procedures based on the judgment of the investigator.
- Age ≥ 18 years at the time of consent.
- Histological confirmation of TNBC defined by ER/PR <10%, HER2 0-1+ by IHC or 2+ by IHC and fluorescence in situ hybridization (FISH) negative.
- Stage II/III TNBC treated with neoadjuvant systemic therapy AND have residual disease defined as RCB II/III at time of surgery.
- Baseline staging scans at the discretion of the treating physician and demonstrate no evidence of metastatic disease.
- The participant must have archival diagnostic tissue and/or surgical resection tissue Available.
- Participants are willing and able to comply with study procedures based on the judgment of the investigator.
You may not qualify if…
- Participants are pregnant or breastfeeding.
Where it is running
- UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.